Invivyd, Inc.
IVVD Healthcare Biotechnology
Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS fell 16.7% and free cash flow fell 226.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow IVVD
Invivyd, Inc. (IVVD) Beneish M-score
Invivyd, Inc.'s Beneish M-score for fiscal 2025 is −1.63; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −1.63 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.61 | — | 0.56 | |
| Gross margin index | 1.01 | — | 0.53 | |
| Asset quality index | 0.48 | — | 0.19 | |
| Sales growth index | 2.10 | — | 1.88 | |
| Depreciation index | 1.11 | — | 0.13 | |
| SG&A index | 0.50 | — | −0.09 | |
| Total accruals to total assets | 0.02 | — | 0.10 | |
| Leverage index | 0.26 | — | −0.08 | |
| Beneish M-score | Flagged by the model | −1.63 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| UPB Upstream Bio, Inc. compare | −2.8× |
| IVVD Invivyd, Inc. | −1.6× |
| CGEN Compugen Ltd. compare | −1.6× |
| RNAC Cartesian Therapeutics, Inc. compare | 8.9× |
| LYEL Lyell Immunopharma, Inc. compare | — |
| ELDN Eledon Pharmaceuticals, Inc. compare | — |
| SION Sionna Therapeutics, Inc. compare | — |
| ACOG Alpha Cognition Inc. compare | — |
| PRQR ProQR Therapeutics N.V. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI